Guardant Health (GH) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
28 Apr, 2026Voting matters and shareholder proposals
Election of two Class II director nominees: Ian Clark and Manuel Hidalgo Medina, both recommended by the board.
Ratification of Deloitte & Touche LLP as the independent registered public accounting firm for the year ending December 31, 2026.
Non-binding advisory vote to approve named executive officer compensation.
Non-binding advisory vote on the frequency of stockholder advisory votes regarding executive compensation, with 'Year' as the recommended frequency.
Other business may be addressed as appropriate during the meeting or any adjournment.
Board of directors and corporate governance
Board recommends the election of two Class II director nominees for continued governance oversight.
Executive compensation and say-on-pay
Advisory vote solicited to approve compensation for named executive officers.
Advisory vote on the frequency of future say-on-pay votes, with annual votes recommended.
Latest events from Guardant Health
- Q1 revenue up 48% to $302M; 2026 guidance raised on strong Oncology and Shield growth.GH
Q1 20268 May 2026 - Record revenue growth, new product launches, and strong governance mark this year's proxy.GH
Proxy filing28 Apr 2026 - Quest partnership and CRC guideline updates drive growth, with Shield revenue set for strong gains.GH
Leerink Global Healthcare Conference 202626 Apr 2026 - Smart platform innovation and Shield’s multi-cancer expansion drive robust 2025 growth and 2026 outlook.GH
44th Annual J.P. Morgan Healthcare Conference22 Apr 2026 - 2025 revenue up 33% to $982M; 2026 outlook targets 27–30% growth and Shield expansion.GH
Q4 202511 Apr 2026 - First-of-its-kind monitoring CDx and rapid Shield adoption fuel strong growth outlook.GH
Barclays 28th Annual Global Healthcare Conference11 Mar 2026 - Strong growth and innovation across all product lines, with major regulatory and commercial catalysts ahead.GH
TD Cowen 46th Annual Health Care Conference4 Mar 2026 - All proposals passed, directors elected, and no stockholder questions were raised.GH
AGM 20243 Feb 2026 - FDA approved Shield as the first blood-based, first-line CRC screening for average-risk adults.GH
FDA Announcement2 Feb 2026